MYC and hepatocellular carcinoma: To investigate the mechanisms limiting the efficacy of Dasatinib against c‐Myc driven mouse HCC, we evaluated the expression levels of Dasatinib targets in vehicle or Dasatinib treated mouse HCC samples.